Literature DB >> 2415178

Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement.

F Hugo, D Jenne, S Bhakdi.   

Abstract

Assembly of the terminal C5b-C9 complement components into the cytolytic C5b-9 complex is accompanied by exposure of characteristic neoantigens on the macromolecule. We report the production and characterization of mouse monoclonal antibodies to C9-dependent neoantigens of human C5b-9. Binding-inhibition assays with EDTA-human plasma and micro-ELISA assays with purified C9 showed that the antibodies did not react with native complement components and thus confirmed the specificity of the antibodies for the neoantigens. The monoclonal antibodies did, however, cross-react with cytolytically inactive, fluid-phase C5b-9 complexes. Thus, expression of the neoantigenic determinants was not dependent on the formation of high molecular weight C9 polymers with the complex, since these are absent in fluid-phase C5b-9. Radioiodinated antibodies could be utilized in immunoradiometric assays for the detection and quantitation of C5b-9 on cell membranes. Cross-reactivities of the antibodies with C9-dependent neoantigens of several other animal species were examined and antibody clones cross-reacting with rabbit (clones 3B1, 3D8, and 2F3), sheep (clones 3D8 and 2F3) and guinea-pig (clone 3D8) neoantigens were identified. Three of four tested clones (3D8, 2F3, 1A12) precipitated C5b-9 complexes in double-diffusion assays, probably due to their interaction with multiple and repeating C9-epitopes on the terminal complexes. The monoclonal antibodies will be of value for definitive identification and quantitation of C5b-9 on cell membranes and in tissues, and for establishing immunoassays for detection and quantitation of terminal fluid-phase C5b-9 complexes in plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415178     DOI: 10.1007/bf01116996

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  14 in total

1.  Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies.

Authors:  R Würzner; H Xu; A Franzke; M Schulze; J H Peters; O Götze
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

2.  Importance of the third thrombospondin repeat of C6 for terminal complement complex assembly.

Authors:  R Würzner; D Mewar; B A Fernie; M J Hobart; P J Lachmann
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

3.  Complement activation within the coeliac small intestine is localised to Brunner's glands.

Authors:  R B Gallagher; C P Kelly; S Neville; O Sheils; D G Weir; C F Feighery
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

4.  Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.

Authors:  S Bhakdi; R Käflein; T S Halstensen; F Hugo; K T Preissner; T E Mollnes
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

5.  Use of a monoclonal antibody to determine the mode of transmembrane pore formation by streptolysin O.

Authors:  F Hugo; J Reichwein; M Arvand; S Krämer; S Bhakdi
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

6.  Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.

Authors:  H Dauchel; P Joly; A Delpech; E Thomine; F Sauger; X Le Loet; P Lauret; F Tron; M Fontaine; J Ripoche
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

7.  Identification with monoclonal antibodies of hemolysin produced by clinical isolates of Escherichia coli.

Authors:  F Hugo; M Arvand; J Reichwein; N Mackman; I B Holland; S Bhakdi
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

8.  Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.

Authors:  F Niculescu; F Hugo; H G Rus; R Vlaicu; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

9.  In vivo clearance studies of the terminal fluid-phase complement complex in rabbits.

Authors:  F Hugo; C Berstecher; S Krämer; W Fassbender; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

10.  Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).

Authors:  T E Mollnes; H Redl; K Høgåsen; A Bengtsson; P Garred; L Speilberg; T Lea; M Oppermann; O Götze; G Schlag
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.